Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 4, Pages 448-455
Publisher
American Society of Clinical Oncology (ASCO)
Online
2012-12-12
DOI
10.1200/jco.2012.41.6180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
- (2011) P. M. Fayers et al. BLOOD
- Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
- (2011) M.-V. Mateos et al. BLOOD
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
- (2011) S. Mailankody et al. BLOOD
- Treatment Options for Relapsed and Refractory Multiple Myeloma
- (2011) Sagar Lonial et al. CLINICAL CANCER RESEARCH
- A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
- (2011) Stefano Sacchi et al. LEUKEMIA & LYMPHOMA
- Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
- (2010) A. Waage et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Optimising patient outcomes in myeloma
- (2010) Jean-Luc Harousseau CANCER TREATMENT REVIEWS
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
- (2010) Meral Beksac et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy
- (2010) A. Siciliano et al. HAEMATOLOGICA
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma
- (2010) Jens Hasskarl et al. LEUKEMIA & LYMPHOMA
- Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (
- (2010) Christopher P. Venner et al. LEUKEMIA & LYMPHOMA
- Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
- (2009) H. Brenner et al. HAEMATOLOGICA
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- (2009) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
- (2008) M.-V. Mateos et al. HAEMATOLOGICA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started